Chronic Inflammatory Demyelinating Polyneuropathy - 04/05/13
, Jonathan Katz, MD bRésumé |
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune disorder of the peripheral nervous system. This article highlights our current understanding of the condition along with its phenotypic variants that are encountered in clinical practice. The diagnostic evaluation of CIDP includes laboratory studies to detect associated medical conditions and electrodiagnostic studies to assess for demyelination. Current treatment options include corticosteroids, plasma exchange, and intravenous immune globulin, along with alternative therapies that may be used as corticosteroid-sparing agents or for treatment-refractory cases. Approximately 85% to 90% of patients eventually improve or stabilize with treatment, and the long-term prognosis of CIDP is favorable.
Le texte complet de cet article est disponible en PDF.Keywords : CIDP, Immune neuropathy, Demyelination, Monoclonal gammopathy, IVIg, Corticosteroids, Plasma exchange
Plan
| Disclosures: Dr Gorson has received compensation from Grifols Pharmaceuticals for speaking engagements and serves on an independent data safety monitoring board and as a consultant for CSL Behring. Dr Katz: None. |
Vol 31 - N° 2
P. 511-532 - mai 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
